Read the Journal of Managed Care + Specialty Pharmacy (JMCP) May 2025 Issue
Spinal Muscular Atrophy Resources
Spinal muscular atrophy (SMA) is a rare, autosomal recessive genetic disease that causes progressive muscle weakness and atrophy. Approximately 6,000 children and adults in the United States are affected, making SMA one of the most common rare diseases. AMCP conducted a virtual Market Insights program to identify perspectives of AMCP members on current and future therapies for SMA.
AMCP Market Insights Summit: Spinal Muscular Atrophy (SMA)
-
Proceedings:
Findings from the AMCP Market Insights Program
Related
In the AMCP Legislative Days 2025 Booklet, learn about AMCP’s position on legislation impacting managed care pharmacy, how to talk to Members of Congress and their staff, and helpful tips for engaging in effective dialogue.
Access the AMCP Legislative Days 2025 Education Slides, to learn the terminology most associated with a Member of Congress and understand key advocacy vocabulary to help explain AMCP’s positions on the The Access to Prescription Digital Therapeutics Act of 2025 (H.R. 3288/S. 1702) The Medicaid VBPs for Patients (MVP) Act (S. 1637) and the Ensuring Community Access to Pharmacist Services Act (H.R. 3164)
Featured News & Resources
See Full Calendar
National Meetings
Midwest AMCP Chicago Day of Education
National Meetings
Mountain West Pharmacy Summit
Other Events
Northeast Day of Education
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
